Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 801

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 801
---
 |
| Decrease in cash and cash equivalents                                      |     |      |   |     |                              |   (877 | ) |     |      | (6,906 | ) |
| Cash and cash equivalents - beginning of period                            |     |      |   |     |                              |  1,535 |   |     |      | 11,780 |   |
| Cash and cash equivalents - end of period                                  |     |      |   |     |                              |    658 |   |     |      |  4,874 |   |
| Supplementary information(note 8)                                          |     |      |   |     |                              |        |   |     |      |        |   |

The accompanying notes are an integral part of these condensed consolidated interim financial statements. F-51

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

| 1 | Nature of operations, corporate history, and going concern and management plans |

Nature of operations

Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing one late-stage therapeutic - REM-001for cutaneous metastatic breast cancer (“CMBC”). In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its current and future product candidates.

Corporate history

The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”).

On August 19, 2020, the Company completed its merger with Adgero Biopharmaceutical